Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Gilead Sciences Inc patents


Recent patent applications related to Gilead Sciences Inc. Gilead Sciences Inc is listed as an Agent/Assignee. Note: Gilead Sciences Inc may have other listings under different names/spellings. We're not affiliated with Gilead Sciences Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Gilead Sciences Inc-related inventors


Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer

Provided herein are methods and compositions for the treatment of cancer. In particular, the methods include administration of a bcl-2 inhibitor and a bet inhibitor.. ... Gilead Sciences Inc

Methods of treating liver disease

The present disclosure relates to a method of preventing and/or treating liver disease comprising administering an ask1 inhibitor in combination with a fxr agonist to a patient in need thereof.. . ... Gilead Sciences Inc

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

Co-crystals, salts and solid forms of tenofovir alafenamide

The present invention relates to co-crystals, salts and crystalline forms of tenofovir alafenamide and methods for preparation, use and isolation of such compounds. . ... Gilead Sciences Inc

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

Phosphonate analogs of hiv inhibitor compounds

The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.. . ... Gilead Sciences Inc

Toll like receptor modulator compounds

This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. Tlr8), and methods of making and using them.. ... Gilead Sciences Inc

Therapeutic compositions for treatment of human immunodeficiency virus

Pharmaceutical formulations suitable for treating viral infections such as hiv are provided, in particular solid oral dosage forms including the compounds of formula i, formula ii, formula iii, formula iv, or pharmaceutically acceptable salts or solvates thereof, and one or more excipients.. . ... Gilead Sciences Inc

Processes and intermediates for preparing anti-hiv agents

The invention provides synthetic processes and synthetic intermediates that can be used to prepare compounds having useful anti-hiv properties.. . ... Gilead Sciences Inc

Salts of hiv inhibitor compounds

The invention is related to salts of anti-viral compounds, compositions containing such salts, and therapeutic methods that include the administration of such salts, as well as to process and intermediates useful for preparing such salts.. . ... Gilead Sciences Inc

03/15/18 / #20180072755

Thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-d]pyrimidines useful for treating respiratory syncitial virus infections

Provided herein are formulations, methods and substituted thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-d]pyrimidine compounds of formula (i) for treating pneumovirinae virus infections, including respiratory syncytial virus infections, as well as methods and intermediates for synthesis of substituted thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-d]pyrimidine compounds.. . ... Gilead Sciences Inc

03/15/18 / #20180071303

Syk inhibitors

The application provides methods reducing the side effects of chemotherapy and radiotherapy, including, hematopoietic toxicity, anemia, myelosuppression, pancytopenia, thrombocytopenia, neutropenia, lymphopenia, leukopenia, stomatitis and alopecia. The application provides a method for increasing the number of, neutrophil counts and platelet counts in a patient in need thereof, comprising administering an effective of an inhibitor of spleen tyrosine kinase (syki). ... Gilead Sciences Inc

03/15/18 / #20180071302

Syk inhibitors

The application provides methods of treating or reducing thrombocytopenia, leukopenia, anemia, or neutropenia in a patient in need thereof, comprising the step of administering an effective amount of a compound selected from compounds 1-6, disclosed herein.. . ... Gilead Sciences Inc

03/08/18 / #the present disclosure provides phosphatidylinositol 3-kinase (pi3k) inhibitors of formula (j),

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

03/08/18 / #20180065986

Sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate

The present invention relates to sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate form i.. . ... Gilead Sciences Inc

03/08/18 / #20180065938

Toll like receptor modulator compounds

This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. Tlr8), and methods of making and using them.. ... Gilead Sciences Inc

02/22/18 / #the present disclosure relates to a compound of formula (ia), (ib), (iia), and (iib):

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

02/15/18 / #20180042946

Topical antiviral formulations

The present invention relates to formulations of antiviral compounds, in particular [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenofovir, pmpa), suitable for topical application, and to their use in the reduction of or prevention of acquisition and transmission of herpes simplex virus.. . ... Gilead Sciences Inc

02/15/18 / #20180042933

Treatment of acvr1-mediated diseases

Provided herein are methods, compositions, and kits for treating acvr-1-mediated diseases using n-(cyanomethyl)-4-[2-4-morpholinoanilino)pyrimidin-4-yl]benzamide.. . ... Gilead Sciences Inc

02/15/18 / #20180042905

Methods of treating hepatitis b virus

The present invention relates to novel methods of treating hepatitis b virus by administering a kdm5 inhibitor.. . ... Gilead Sciences Inc

02/08/18 / #20180036289

Cobicistat for use in cancer treatments

The disclosure describes methods for and compositions for treatment of patients having cancers expressing cyp3a enzymes by co-administration of cobicistat with an anticancer agent.. . ... Gilead Sciences Inc

01/25/18 / #the present disclosure provides processes for the preparation of a compound of formula:

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

01/25/18 / #20180022757

Synthesis of polycyclic-carbamoylpyridone compounds

Methods of making compounds of formula i are disclosed:. . ... Gilead Sciences Inc

01/18/18 / #20180016280

Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections

Provided herein are formulations, methods and substituted tetrahydrofuranyl-pyrrolo[1,2-f][1,2,4]triazine-4-amine compounds of formula (i) for treating pneumovirinae virus infections, including respiratory syncytial virus infections, as well as methods and intermediates for synthesis of tetrahydrofuranyl-pyrrolo[1,2-f][1,2,4]triazine-4-amine compounds.. . ... Gilead Sciences Inc

01/11/18 / #disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula i:

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

01/04/18 / #20180002316

Cot modulators and methods of use thereof

The present disclosure relates generally to modulators of cot (cancer osaka thyroid) and methods of use and manufacture thereof.. . ... Gilead Sciences Inc

12/28/17 / #20170369502

Antiviral compounds

The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.. . ... Gilead Sciences Inc

12/28/17 / #20170369444

Inhibitors of histone demethylases

Compounds of the form in which q is selected from —cooh—ch═nr12, —w, —ch2nhr13, —ch=0 and —ch(or17)2 capable of modulating the activity of histone demethylases (hdmes), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. Cancer and formulations and methods of use of such compounds.. ... Gilead Sciences Inc

12/21/17 / #the invention provides compounds of formula i or formula ii:

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

12/21/17 / #20170362201

Cot modulators and methods of use thereof

The present disclosure relates generally to modulators of cot (cancer osaka thyroid) and methods of use and manufacture thereof.. . ... Gilead Sciences Inc

12/14/17 / #20170355694

Fxr (nr1h4) modulating compounds

The present disclosure relates generally to compounds which bind to the nr1h4 receptor (fxr) and act as agonists of fxr. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.. ... Gilead Sciences Inc

12/14/17 / #20170355693

Fxr (nr1h4) modulating compounds

The present disclosure relates generally to compounds which bind to the nr1h4 receptor (fxr) and act as agonists of fxr. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.. ... Gilead Sciences Inc

12/14/17 / #20170355685

Fxr (nr1h4) modulating compounds

The present disclosure relates generally to compounds which bind to the nr1h4 receptor (fxr) and act as agonists of fxr. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.. ... Gilead Sciences Inc

11/30/17 / #20170342079

Compounds and methods for antiviral treatment

Compounds and pharmaceutically acceptable salts and esters and compositions thereof, for treating viral infections are provided. The compounds and compositions are useful for treating pneumovirinae virus infections. ... Gilead Sciences Inc

11/30/17 / #20170342068

Compounds for the treatment of hepatitis b virus infection

The present disclosure generally relates to compounds and pharmaceutical compositions which may be used in methods of treating a hepatitis b virus infection.. . ... Gilead Sciences Inc

11/23/17 / #20170333438

Crystalline forms of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide

The present invention relates to crystalline forms and co-crystals of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide, the pharmaceutical formulations, and the therapeutic uses thereof. The present invention also relates to novel crystalline forms of sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate form i.. ... Gilead Sciences Inc

11/16/17 / #20170327595

Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2)

Provided are therapeutic, diagnostic, and prognostic methods for disease, including diseases associated with fibrosis and cancer using agents that bind to, inhibit, and/or detect lysyl oxidase-like 2 (loxl2), and agents, compositions, kits, assay systems, and devices for use with such methods.. . ... Gilead Sciences Inc

11/16/17 / #20170327526

2'-chloro aminopyrimidinone and pyrimidine dione nucleosides

Provided herein are formulations, methods and substituted 2′-chloro aminopyrimidinone and pyrimidine dione compounds of formula (i) for treating pneumovirinae virus infections, including respiratory syncytial virus infections, as well as methods and intermediates for synthesis of substituted 2′-chloro aminopyrimidinone and pyrimidine dione compounds.. . ... Gilead Sciences Inc

10/26/17 / #20170306050

Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases

The present disclosure provides compositions and methods of use comprising a matrix metalloproteinase-9 (mmp9) binding protein, alone or in combination with one or more additional therapeutic agents for the treatment or prevention of diseases and conditions.. . ... Gilead Sciences Inc

10/12/17 / #compounds of formula i are disclosed

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

10/05/17 / #20170281627

Toll like receptor modulator compounds

The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 d] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. Tlr-8), and methods of making and using them.. ... Gilead Sciences Inc

09/28/17 / #20170273994

Compositions and methods for combination antiviral therapy

The present invention relates to therapeutic combinations of [2-(6-amino-purin-9 yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, viread®) and (2r, 5s, cis)-4-amino-5-fluoro-1-(2 hydroxymethyl-1,3-oxathiolan-5-yl)-(1h)-pyrimidin-2-one (emtricitabine, emtriva™, (−)-cis ftc) and their physiologically functional derivatives. The combinations may be useful in the treatment of hiv infections, including infections with hiv mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. ... Gilead Sciences Inc

09/28/17 / #20170273952

Methods of treating liver disease

The present disclosure relates to a method of preventing and/or treating liver disease comprising administering an ask1 inhibitor in combination with a fxr agonist, to a patient in need thereof.. . ... Gilead Sciences Inc

09/21/17 / #crystalline forms of the anti-hcv compound (1ar,5s,8s,9s,10r,22ar)-5-tert-butyl-n-[(1r,2r)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-9-ethyl-18,18-difluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8h-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide (compound i) were prepared and characterized in the solid state:

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

09/21/17 / #20170269085

Lysyl oxidase-like 2 assay and methods of use thereof

The present disclosure provides an assay to detect and/or quantify circulating lysyl oxidase-like 2 (loxl2) polypeptides in an individual. The assay is useful in diagnostic and prognostic applications, which are also provided.. ... Gilead Sciences Inc

09/14/17 / #disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula i:

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

09/14/17 / #compounds for use in the treatment of human immunodeficiency virus (hiv) infection are disclosed. the compounds have the following formula (i):

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

08/17/17 / #the present disclosure provides processes for the preparation of a compound of formula:

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

08/17/17 / #20170232019

Compositions and methods for combination antiviral therapy

The present invention relates to therapeutic combinations of [2-(6-amino-purin-9 yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, viread®) and (2r, 5s, cis)-4-amino-5-fluoro-1-(2 hydroxymethyl-1,3-oxathiolan-5-yl)-(1h)-pyrimidin-2-one (emtricitabine, emtriva™, (−)-cis ftc) and their physiologically functional derivatives. The combinations may be useful in the treatment of hiv infections, including infections with hiv mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. ... Gilead Sciences Inc

08/10/17 / #provided are methods for treating orthomyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of formula i:

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

08/03/17 / #the present invention relates to a compound of formula (i):

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

08/03/17 / #20170217952

Crystalline form

The invention provides a crystalline form of the compound of formula (ia), methods for making the crystalline form of the compound of formula (ia), and therapeutic methods for the use of the crystalline form of the compound of formula (ia).. . ... Gilead Sciences Inc

07/27/17 / #the present disclosure provides processes for the preparation of a compound of formula i:

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

07/27/17 / #crystalline forms of 5-(4-cyclopropyl-1h-imidazol-1-yl)-n-(6-(4-isopropyl-4h-1,2,4-triazol-3-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide (compound i) were prepared and characterized in the solid state:

Gilead Sciences, Inc

. . ... Gilead Sciences Inc

07/27/17 / #20170210770

Phosphonate analogs of hiv inhibitor compounds

The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.. . ... Gilead Sciences Inc

07/13/17 / #the present invention relates to compounds of formula (i):

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

07/13/17 / #20170197985

Sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate

The present invention relates to sodium (2r,5s,13ar)-7,9-dioxo-10 ((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5] pyrazino[2,1-b][1,3]oxazepin-8-olate form i.. . ... Gilead Sciences Inc

07/06/17 / #the invention provides compounds of formula i or formula ii:

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

07/06/17 / #provided are compounds of formula i:

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

07/06/17 / #20170190763

Human immunodeficiency virus neutralizing antibodies

The present invention provides novel anti-hiv antibodies with improved therapeutic properties, related pharmaceutical compositions, and methods of use thereof.. . ... Gilead Sciences Inc

07/06/17 / #20170189337

Therapeutic compositions for treatment of human immunodeficiency virus

A solid oral dosage form is provided, comprising a compound of formula i or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.. . ... Gilead Sciences Inc

06/22/17 / #the present invention relates to compounds of formula (i):

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

06/22/17 / #20170174788

Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders

Provided herein are methods and pharmaceutical compositions for the treatment of inflammatory disorders comprising filgotinib and a matrix metalloproteinase-9 (mmp9) binding protein.. . ... Gilead Sciences Inc

06/22/17 / #20170174713

Tank-binding kinase inhibitor compounds

Compounds having the following formula (i) and methods of their use and preparation are disclosed:. . ... Gilead Sciences Inc

06/22/17 / #20170173034

Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders

Provided herein are methods and pharmaceutical compositions for the treatment of inflammatory disorders comprising filgotinib and a syk inhibitor.. . ... Gilead Sciences Inc

06/08/17 / #the present application provides for a compound of formula iv,

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

06/01/17 / #20170152240

Cot modulators and methods of use thereof

The present disclosure relates generally to modulators of cot (cancer osaka thyroid) and methods of use and manufacture thereof.. . ... Gilead Sciences Inc

05/18/17 / #20170137405

Compounds for the treatment of hiv

The invention provides compounds of formula (i): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (i), processes for preparing compounds of formula (i), intermediates useful for preparing compounds of formula i and therapeutic methods for treating a retroviridae viral infection including an infection caused by the hiv virus.. ... Gilead Sciences Inc

05/18/17 / #20170136016

Method for treating a pulmonary hypertension condition

A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (pah) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years. . ... Gilead Sciences Inc

05/18/17 / #20170136001

Method of treating a viral infection using elvitegravir combinations

The invention includes methods, compositions, and kits useful for treating a viral infection by administering 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with atazanavir or a pharmaceutically acceptable salt thereof, and optionally with a compound that inhibits cytochrome p-450, or a pharmaceutically acceptable salt thereof.. . ... Gilead Sciences Inc

05/18/17 / #20170136000

Method of treating a viral infection using elvitegravir combinations

The invention includes methods, compositions, and kits useful for treating a viral infection by coadministering 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, with lopinavir or a pharmaceutically acceptable salt thereof.. . ... Gilead Sciences Inc

05/11/17 / #compounds for use in the treatment of human immunodeficiency virus (hiv) infection are disclosed. the compounds have the following formula (i):

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

05/04/17 / #compounds for use in the treatment of human immunodeficiency virus (hiv) infection are disclosed. the compounds have the following formula (ia):

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

04/27/17 / #provided are compounds of formula i,

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

04/27/17 / #compounds for use in the treatment of human immunodeficiency virus (hiv) infection are disclosed. the compounds have the following formula (i):

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

04/27/17 / #20170114048

Compounds and combinations for the treatment of hiv

Provided are compounds, compositions, combinations, kits, uses, and methods for treating hiv in a human being using such compounds or combinations with proteasome inhibitors.. . ... Gilead Sciences Inc

03/30/17 / #the present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. in particular embodiments, the structure of the compounds is given by formula i:

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

03/30/17 / #the invention provides compounds of formula i:

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

03/30/17 / #20170088576

Antiviral compounds

The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.. . ... Gilead Sciences Inc

03/23/17 / #20170079999

Unitary pharmaceutical dosage form

In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir df are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir df (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.. ... Gilead Sciences Inc

03/16/17 / #provided are methods for treating arenaviridae and coronaviridae virus infections by administering nucleosides and prodrugs thereof, of formula i:

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

03/16/17 / #20170071944

Modulators of toll-like receptors for the treatment of hiv

Provided are methods, uses, pharmaceutical regimens, pharmaceutical compositions, and kits comprising modulators of tlr8 and pharmaceutically acceptable salts thereof, useful in treating hiv infections.. . ... Gilead Sciences Inc

03/02/17 / #compounds for use in the treatment of human immunodeficiency virus (hiv) infection are disclosed. the compounds have the following formula (i):

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

03/02/17 / #20170056424

Solid forms of tenofovir

The present invention relates to solid forms of tenofovir and methods for preparation, use and isolation of such forms.. . ... Gilead Sciences Inc

03/02/17 / #20170056423

Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections

The use of the hemifumarate form of {9-[(r)-2-[[(s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine} (tenofovir alafenamide hemifumarate) in combination with cobicistat is disclosed. In addition, the combination of tenofovir alafenamide hemifumarate, cobicistat, emtricitabine, and elvitegravir, and the combination of tenofovir alafenamide hemifumarate, cobicistat, emtricitabine, and darunavir, are disclosed.. ... Gilead Sciences Inc

02/16/17 / #20170042961

Methods for treating hcv

This invention relates to combinations of therapeutic molecules useful for treating hepatitis c virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.. ... Gilead Sciences Inc

02/09/17 / #the present disclosure relates to compounds that are syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. in particular embodiments, the structure of the compounds is given by formula i:

Gilead Sciences, Inc.

. . ... Gilead Sciences Inc

02/02/17 / #20170029427

Compounds and methods for antiviral treatment

Compounds and pharmaceutically acceptable salts and esters and compositions thereof, for treating viral infections are provided. The compounds and compositions are useful for treating pneumovirinae virus infections. ... Gilead Sciences Inc

01/19/17 / #20170014389

Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections

A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by escherichia coli, klebsiella pneumoniae, klebsiella oxytoca, pseudomonas aeruginosa, haemophilus influenzae, proteus mirabilis, enterobacter species, serratia marcescens as well as those caused by burkholderia cepacia, stenotrophomonas maltophilia, alcaligenes xylosoxidans, and multidrug resistant pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.. . ... Gilead Sciences Inc

01/12/17 / #20170008905

Cot modulators and methods of use thereof

The present disclosure relates generally to modulators of cot (cancer osaka thyroid) and methods of use and manufacture thereof.. . ... Gilead Sciences Inc

01/12/17 / #20170008897

Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections

Provided herein are formulations, methods and substituted tetrahydrofuranyl-pyrrolo[1,2-f][1,2,4]triazine-4-amine compounds of formula (i) for treating pneumovirinae virus infections, including respiratory syncytial virus infections, as well as methods and intermediates for synthesis of tetrahydrofuranyl-pyrrolo[1,2-f][1,2,4]triazine-4-amine compounds.. . ... Gilead Sciences Inc

01/12/17 / #20170008873

Cot modulators and methods of use thereof

The present disclosure relates generally to modulators of cot (cancer osaka thyroid) and methods of use and manufacture thereof.. . ... Gilead Sciences Inc

01/12/17 / #20170007617

Intravenous formulations of a late sodium current inhibitor

An intravenous pharmaceutical composition or kit comprising 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2h)-one (compound i) and a beta-cyclodextrin derivative.. . ... Gilead Sciences Inc

01/05/17 / #20170000807

Pharmaceutical formulations

The invention provides a solid oral dosage form comprising tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.. . ... Gilead Sciences Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Gilead Sciences Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Gilead Sciences Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###